Research Article Details

Article ID: A26679
PMID: 19961393
Source: Clin Chem Lab Med
Title: Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults.
Abstract: BACKGROUND: Increased uric acid is associated with the metabolic syndrome, conditions linked to oxidative stress and insulin resistance. Non-alcoholic fatty liver disease (NAFLD) is now considered a hepatic manifestation of insulin resistance. However, little has been written regarding the association between uric acid and NAFLD. METHODS: We examined the association between uric acid and the presence of NAFLD in 3768 Koreans (2133 men, 1635 women; aged 20-75 years) in a health examination program. Uric acid quartiles were categorized separately as follows: Q1: <or=291.5, Q2: 291.6-333.1, Q3: 333.2-380.7, and Q4: >or=380.8 micromol/L for men; Q1: <or=202.2, Q2: 202.3-232.0, Q3: 231.1-267.7, and Q4: >or=267.8 micromol/L for women. Hepatic steatosis was diagnosed based on abdominal ultrasonographic findings by hyperechogenicity of liver tissue, difference of echogenicity between the liver and diaphragm, and visibility of vascular structures. The odds ratios (ORs) and 95% confidence intervals (CIs) for NAFLD were calculated across each quartile of serum uric acid. RESULTS: The prevalence of NAFLD was 25.8% (32.2% in men and 17.4% in women). After adjustment for age, body mass index (BMI), smoking, regular exercise, blood pressure, fasting plasma glucose (FPG), triglycerides, and high-density lipoprotein (HDL) cholesterol, the ORs (95% CIs) for NAFLD according to each quartile of uric acid were 1.00, 1.55 (1.13-2.14), 1.77 (1.30-2.41), and 2.01 (1.45-2.78) for men and 1.00, 0.69 (0.40-1.20), 1.12 (0.67-1.88), and 1.94 (1.21-3.13) for women. CONCLUSIONS: Serum uric acid is independently associated with the presence of NAFLD, and uric acid may be a useful additional measure in assessing the risk of NAFLD in the clinical setting.
DOI: 10.1515/CCLM.2010.037

Strategy ID Therapy Strategy Synonyms Therapy Targets Therapy Drugs
S08 Lifestyle measures Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise -- -- Details
S01 Improve insulin resistance insulin sensitizer; insulin resistance; glucose tolerance Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide Details
S04 Anti-oxidative stress oxidative stress α-tocopherol: antioxidant Vitamin E Details

Target ID Target Name GENE Action Class UniProtKB ID Entry Name
T18 Acetyl-CoA carboxylase 1 ACACA inhibitor Enzyme Q13085 ACACA_HUMAN Details
T20 Fatty acid synthase FASN inhibitor Enzyme P49327 FAS_HUMAN Details
T21 Diacylglycerol O-acyltransferase 2 DGAT2 inhibitor Enzyme Q96PD7 DGAT2_HUMAN Details

Diseases ID DO ID Disease Name Definition Class
I05 9352 Type 2 diabetes mellitus A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus Details

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D328 Serine Chemical drug DB00133 SRR Improve insulin resistance Under clinical trials Details
D080 Citrulline Chemical drug DB00155 -- -- Under clinical trials Details
D182 Insulin Biological drug DB00030 INSR agonist; CPE modulator&product of -- Under clinical trials Details
D094 Cysteamine Chemical drug DB00847 GSS stimulant Renal drug Under clinical trials Details
D095 Cysteamine bitartrate Chemical drug DB00847 -- -- Under clinical trials Details